Considering Adipose Mesenchymal Stromal/Stem Cells

By Jonathan Carson

The last decade shows us a trend that bucks conventional wisdom. When we segment the numbers of annual hAD-MSC trials into autologous and allogeneic groups, there’s a surprise. Beginning around 2015, hAD-MSCs are much less monopolized by autologous uses.

Allogeneic or not, hAD-MSCs have been growing in clinical trial presence over the last decade. We already know that adipose is a large-volume tissue that’s highly enriched in MSCs.

Allogeneic cells can derive from a fully characterized, quality-controlled source that can be cryogenically stored. Also, the desired cells can be isolated and expanded—with qualified materials—out of an industrialized supply chain to obtain a master cell bank (MCB) and its “daughter” working cell bank (WCB). Learn more on why allogeneic MSCs could be a favorable option in comparison with autologous MSCs.